Ann: CEO's AGM Address and Presentation-SRX.AX, page-20

I think the number of patients MIA will be low. Patients with cancer are well motivated to be under follow up care either to continue receiving medication or to have some other treatment including surgery or end stage palliative care in the hospital system, and should be easy to track down through hospitals, medical practitioners, relatives and the internet.

I personally think that Sirtex probably don't know very much about the details of the SARAH trial delay, and we will just have to wait and see. But looking at it from the reverse prespective, presumably if the treatment was an abysmal failure, there wouldn't be any delay.

Anyway, I am still confident that "double digit growth" is SRXspeak for a continuation in the current growth, and surprises will be to the upside. My spreadsheet predicts a price at the end of the next financial year at $43, and I see no reason to doubt it.